Literature DB >> 34209278

NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells.

Wen-Jing Liu1, Ying-Xue Huang1, Wei Wang1, Ye Zhang1, Bing-Jie Liu1, Jian-Ge Qiu1, Bing-Hua Jiang2, Ling-Zhi Liu3.   

Abstract

Development of resistance to therapy in ovarian cancer is a major hinderance for therapeutic efficacy; however, new mechanisms of the resistance remain to be elucidated. NADPH oxidase 4 (NOX4) is responsible for higher NADPH activity to increase reactive oxygen species (ROS) production. In this study, we showed that higher levels of NOX4 were detected in a large portion of human ovarian cancer samples. To understand the molecular mechanism of the NOX4 upregulation, we showed that NOX4 expression was induced by HIF-1α and growth factor such as IGF-1. Furthermore, our results indicated that NOX4 played a pivotal role in chemotherapy and radiotherapy resistance in ovarian cancer cells. We also demonstrated that NOX4 knockdown increased sensitivity of targeted therapy and radiotherapy through decreased expression of HER3 (ERBB3) and NF-κB p65. Taken together, we identified a new HIF-1α/NOX4 signal pathway which induced drug and radiation resistance in ovarian cancer. The finding may provide a new option to overcome the therapeutic resistance of ovarian cancer in the future.

Entities:  

Keywords:  HER3; HIF-1α; NOX4; ovarian cancer; therapeutic resistance

Year:  2021        PMID: 34209278     DOI: 10.3390/cells10071647

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  27 in total

1.  Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation.

Authors:  Jun He; Qing Xu; Yi Jing; Faton Agani; Xu Qian; Richard Carpenter; Qi Li; Xin-Ru Wang; Stephen S Peiper; Zhimin Lu; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  EMBO Rep       Date:  2012-11-13       Impact factor: 8.807

2.  NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme.

Authors:  Chia-Hung Hsieh; Chung-Pu Wu; Hsu-Tung Lee; Ji-An Liang; Chun-Yen Yu; Yu-Jung Lin
Journal:  Free Radic Biol Med       Date:  2012-06-16       Impact factor: 7.376

3.  The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1.

Authors:  Isabel Diebold; Andreas Petry; John Hess; Agnes Görlach
Journal:  Mol Biol Cell       Date:  2010-04-28       Impact factor: 4.138

4.  Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor.

Authors:  Chang Xia; Qiao Meng; Ling-Zhi Liu; Yongyut Rojanasakul; Xin-Ru Wang; Bing-Hua Jiang
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

Review 5.  Molecular mechanisms of drug resistance in ovarian cancer.

Authors:  Leyla Norouzi-Barough; Mohammad Reza Sarookhani; Mohammadreza Sharifi; Sahar Moghbelinejad; Saranaz Jangjoo; Rasoul Salehi
Journal:  J Cell Physiol       Date:  2018-01-04       Impact factor: 6.384

Review 6.  Biomarkers in ovarian cancer: To be or not to be.

Authors:  Rebecca Arend; Alba Martinez; Tomasz Szul; Michael J Birrer
Journal:  Cancer       Date:  2019-12-15       Impact factor: 6.860

7.  Does IGF-1 play a role in the biology of ovarian cancer?

Authors:  Dominika Majchrzak-Baczmańska; Andrzej Malinowski; Ewa Głowacka; Miłosz Wilczyński
Journal:  Ginekol Pol       Date:  2018       Impact factor: 1.232

Review 8.  Targeting HER2 in ovarian and uterine cancers: challenges and future directions.

Authors:  Eleonora Teplinsky; Franco Muggia
Journal:  Gynecol Oncol       Date:  2014-09-16       Impact factor: 5.482

9.  Overexpression of HER2/HER3 and clinical feature of ovarian cancer.

Authors:  Ye Won Chung; Seongmin Kim; Jin Hwa Hong; Jae Kwan Lee; Nak Woo Lee; Young Seok Lee; Jae Yun Song
Journal:  J Gynecol Oncol       Date:  2019-09       Impact factor: 4.401

10.  Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.

Authors:  Ken Suzawa; Shinichi Toyooka; Masakiyo Sakaguchi; Mizuki Morita; Hiromasa Yamamoto; Shuta Tomida; Tomoaki Ohtsuka; Mototsugu Watanabe; Shinsuke Hashida; Yuho Maki; Junichi Soh; Hiroaki Asano; Kazunori Tsukuda; Shinichiro Miyoshi
Journal:  Cancer Sci       Date:  2015-12-03       Impact factor: 6.716

View more
  7 in total

Review 1.  Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis.

Authors:  Chin-Lin Guo
Journal:  Front Cell Dev Biol       Date:  2022-06-14

Review 2.  NADPH Oxidase 4: A Potential Therapeutic Target of Malignancy.

Authors:  Shulei Gong; Shiyang Wang; Mingrui Shao
Journal:  Front Cell Dev Biol       Date:  2022-05-11

Review 3.  Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment.

Authors:  Margarita Neganova; Junqi Liu; Yulia Aleksandrova; Sergey Klochkov; Ruitai Fan
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

Review 4.  NOX4: a potential therapeutic target for pancreatic cancer and its mechanism.

Authors:  Yawei Bi; Xiao Lei; Ningli Chai; Enqiang Linghu
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

5.  Prognostic Value of NOX4 Expression in Cancer Patients: A Systematic Review and Meta-analysis.

Authors:  Hyun Min Koh; Bo Gun Jang; Chang Lim Hyun; Dong Chul Kim
Journal:  Dis Markers       Date:  2022-02-28       Impact factor: 3.434

Review 6.  ROS and miRNA Dysregulation in Ovarian Cancer Development, Angiogenesis and Therapeutic Resistance.

Authors:  David C Stieg; Yifang Wang; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

Review 7.  Insulin-like growth factor-1 signaling in the tumor microenvironment: Carcinogenesis, cancer drug resistance, and therapeutic potential.

Authors:  Armel H Nwabo Kamdje; Paul F Seke Etet; Maulilio J Kipanyula; Lorella Vecchio; Richard Tagne Simo; Alfred K Njamnshi; Kiven E Lukong; Patrice N Mimche
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-09       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.